RALEIGH, N.C., June 11, 2021 (GLOBE NEWSWIRE) Marius Pharmaceuticals, a patient-centric healthcare company focusing on therapies designed for hypogonadism, more commonly known as testosterone deficiency, today announced the publication of a study on the effects of oral testosterone undecanoate KYZATREX™ on ambulatory blood pressure in hypogonadal men in The Journal of Clinical Hypertension. “Effects of Oral Testosterone Undecanoate KYZATREX™ on Ambulatory Blood Pressure in Hypogonadal Men” wa
SEATTLE, May 04, 2021, (PHARMIWEB) Worldwide Androgen Replacement Therapy Market, By Product Type (Creams/Gels, Patches, Injections, Implants, and Oral Tablets/Capsules/Gums), By Active Ingredient Type (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, and Testosterone Cypionate),.
email article
The FDA accepted a new drug application and set a review date of October 31 for Marius Pharmaceuticals Kyzatrex, an oral testosterone undecanoate softgel, for primary and secondary male hypogonadism.
The Endocrine Society released a new scientific statement calling for more research into the sex differences between males and females. (
Endocrine Reviews)
The American Medical Association has recognized a CPT code (category III) for laser ablation of benign thyroid nodules under imaging guidance, going into effect January 2022, National Ultrasound announced.
Entera Bio s oral human parathyroid hormone succeeded in a 6-month phase II trial at building bone in postmenopausal women with osteoporosis.